US 11,939,292 B1
Aza-substituted psilocin analogs and methods of synthesizing the same
Denton W. Hoyer, West Haven, CT (US); and Robert F. Roscow, Longmont, CO (US)
Assigned to Mydecine Innovations Group Inc., Denver, CO (US)
Filed by Mydecine Innovations Group Inc., Denver, CO (US)
Filed on Nov. 1, 2023, as Appl. No. 18/386,021.
Application 18/386,021 is a continuation of application No. 18/142,010, filed on May 1, 2023.
Application 18/142,010 is a continuation in part of application No. PCT/US2022/031945, filed on Jun. 2, 2022.
Application 18/386,021 is a continuation in part of application No. PCT/US2021/061826, filed on Dec. 3, 2021.
Claims priority of provisional application 63/121,052, filed on Dec. 3, 2020.
Int. Cl. C07D 209/14 (2006.01); C07D 209/12 (2006.01); C07D 209/16 (2006.01); C07D 471/04 (2006.01)
CPC C07D 209/14 (2013.01) [C07D 209/12 (2013.01); C07D 209/16 (2013.01); C07D 471/04 (2013.01)] 6 Claims
 
1. A psilocin analog compound comprising:

OG Complex Work Unit Chemistry
wherein
X1 is CH;
X2 is CH;
X3 is N, or NH;
A is C;
R1 is O, or —OH;
R2 is linear alkane-R3, wherein R3 is (CH3)2NH (dimethylamine); and wherein said dashed lines represents possible double bond positions according to the configuration of X being N or CH, and R1 being O or —OH; or
a pharmaceutically acceptable salt thereof.